Biomarkers
High Expression of SMO and GLI1 Genes with Poor Prognosis in Malignant Mesothelioma
Biomed Research International 2023 April 24 [Link] Guan-Ying Ma, Shuai Shi, Yin-Zhou Sang, Ping Wang, Zhi-Gang Zhang Abstract Background: To investigate the value of SMO and GLI1 genes in the hedgehog pathway in malignant mesothelioma specimens. Further study on the expression and prognosis of SMO and GLI1 in malignant mesothelioma tissues and the relationship between…
Read MorePrognostic significance of inflammation-related and electrolyte laboratory variables in patients with malignant pleural mesothelioma
Frontiers in Medicine 2023 April 5 [Link] Yuan Zhang, Jie Li, Shu Zhang Abstract Objective: Malignant pleural mesothelioma (MPM) is a kind of pleural cancer characterized by low incidence but high invasiveness. There is heterogeneity in survival among patients with MPM. Inflammation-related and electrolyte laboratory variables were previously reported as potential predictors of survival. We…
Read MoreEpigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos
Scientific Reports 2023 April 20 [Link] Giulia Di Mauro, Francesca Frontini, Elena Torreggiani, Maria Rosa Iaquinta, Andrea Caselli, Chiara Mazziotta, Valentina Esposito, Elisa Mazzoni, Roberta Libener, Federica Grosso, Antonio Maconi, Fernanda Martini, Ilaria Bononi, Mauro Tognon Abstract The epigenetic role of microRNAs is established at both physiological and pathological levels. Dysregulated miRNAs and their targets…
Read MoreSurgical phenotype of patients with peritoneal mesothelioma and a germline mutation
Cancer 2023 April 12 [Link] Yaniv Berger, Meghana Gadiraju, Ankit Dhiman, Katie Gilliam, Buerkley Opalecky, Heather Chen, Maria Helgeson, Oliver S Eng, Aliya N Husain, Michael W Drazer, Hedy L Kindler, Jane E Churpek, Kiran K Turaga Abstract Background: This study aimed to investigate if peritoneal mesothelioma (PM) patients with germline mutations (GM) have distinct…
Read MoreDamage-associated molecular patterns and sensing receptors based molecular subtypes in malignant pleural mesothelioma and implications for immunotherapy
Frontiers in Immunology 2023 March 24 [Link] Zheng Liu, Rui Wan, Hua Bai, Jie Wang Abstract Objectives: Malignant pleural mesothelioma (MPM) is characterized as an incredibly aggressive form of cancer with a dismal diagnosis and a dearth of specific biomarkers and therapeutic options. For MPM patients, the effectiveness of immunotherapy may be influenced by damage-associated…
Read MoreExcess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
Frontiers in Immunology 2023 March 24 [Link] Mégane Willems, Arnaud Scherpereel, Eric Wasielewski, Jo Raskin, Hélène Brossel, Alexis Fontaine, Mélanie Grégoire, Louise Halkin, Majeed Jamakhani, Vincent Heinen, Renaud Louis, Bernard Duysinx, Malik Hamaidia, Luc Willems Abstract Background: Only a fraction of patients with malignant pleural mesothelioma (MPM) will respond to chemo- or immunotherapy. For the…
Read MoreThe cytological features of effusions with mesothelioma in situ: A report of 9 cases
Diagnostic Cytopathology 2023 March 21 [Link] Claire W Michael, Carlos C W M Bedrossian, Navid Sadri, Sonja Klebe Abstract Introduction: The diagnosis of mesothelioma in situ (MIS) is now accepted by the WHO as a pre-invasive neoplastic mesothelial proliferation and considered a diagnosis based on histologic evaluation only. Although the definition of MIS includes recurrent…
Read MoreTROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy
Lung Cancer 2023 April [Link] Luca Hegedüs, Özlem Okumus, Fabian Mairinger, Till Ploenes, Sebastian Reuter, Martin Schuler, Anja Welt, Silvia Vega-Rubin-de-Celis, Dirk Theegarten, Agnes Bankfalvi, Clemens Aigner, Balazs Hegedüs Abstract Objectives: Malignant pleural mesothelioma (MPM) is an aggressive cancer which at large is not amenable to curative surgery. Despite the recent approval of immune checkpoint…
Read MoreThe Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
Journal of Clinical Medicine 2023 February 22 [Link] Maxime Borgeaud, Floryane Kim, Alex Friedlaender, Filippo Lococo, Alfredo Addeo, Fabrizio Minervini Abstract Malignant pleural mesothelioma (MPM) is a rare cancer usually caused by asbestos exposure and associated with a very poor prognosis. After more than a decade without new therapeutic options, immune checkpoint inhibitors (ICIs) demonstrated…
Read MoreA novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma
Pathology 2023 February 4 [Link] Yagiz Aksoy, Angela Chou, Mahiar Mahjoub, Amy Sheen, Loretta Sioson, Mahsa S Ahadi, Anthony J Gill, Talia L Fuchs Abstract Recent advances in the management of diffuse pleural mesothelioma (DPM) have increased interest in prognostication and risk stratification on the basis that maximum benefit of combination immunotherapy appears to be…
Read More